169 related articles for article (PubMed ID: 32306101)
1. Cerebrospinal fluid penetration of the colony-stimulating factor-1 receptor (CSF-1R) inhibitor, pexidartinib.
Shankarappa PS; Peer CJ; Odabas A; McCully CL; Garcia RC; Figg WD; Warren KE
Cancer Chemother Pharmacol; 2020 May; 85(5):1003-1007. PubMed ID: 32306101
[TBL] [Abstract][Full Text] [Related]
2. A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors.
Lee JH; Chen TW; Hsu CH; Yen YH; Yang JC; Cheng AL; Sasaki SI; Chiu LL; Sugihara M; Ishizuka T; Oguma T; Tajima N; Lin CC
Invest New Drugs; 2020 Feb; 38(1):99-110. PubMed ID: 30825104
[TBL] [Abstract][Full Text] [Related]
3. The plasma and cerebrospinal fluid pharmacokinetics of sorafenib after intravenous administration in non-human primates.
Kim A; McCully C; Cruz R; Cole DE; Fox E; Balis FM; Widemann BC
Invest New Drugs; 2012 Apr; 30(2):524-8. PubMed ID: 21072558
[TBL] [Abstract][Full Text] [Related]
4. Plasma and cerebrospinal fluid pharmacokinetics of select chemotherapeutic agents following intranasal delivery in a non-human primate model.
League-Pascual JC; Lester-McCully CM; Shandilya S; Ronner L; Rodgers L; Cruz R; Peer CJ; Figg WD; Warren KE
J Neurooncol; 2017 May; 132(3):401-407. PubMed ID: 28290002
[TBL] [Abstract][Full Text] [Related]
5. Pexidartinib, a Novel Small Molecule CSF-1R Inhibitor in Use for Tenosynovial Giant Cell Tumor: A Systematic Review of Pre-Clinical and Clinical Development.
Benner B; Good L; Quiroga D; Schultz TE; Kassem M; Carson WE; Cherian MA; Sardesai S; Wesolowski R
Drug Des Devel Ther; 2020; 14():1693-1704. PubMed ID: 32440095
[TBL] [Abstract][Full Text] [Related]
6. Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study.
Butowski N; Colman H; De Groot JF; Omuro AM; Nayak L; Wen PY; Cloughesy TF; Marimuthu A; Haidar S; Perry A; Huse J; Phillips J; West BL; Nolop KB; Hsu HH; Ligon KL; Molinaro AM; Prados M
Neuro Oncol; 2016 Apr; 18(4):557-64. PubMed ID: 26449250
[TBL] [Abstract][Full Text] [Related]
7. Phase Ib study of the combination of pexidartinib (PLX3397), a CSF-1R inhibitor, and paclitaxel in patients with advanced solid tumors.
Wesolowski R; Sharma N; Reebel L; Rodal MB; Peck A; West BL; Marimuthu A; Severson P; Karlin DA; Dowlati A; Le MH; Coussens LM; Rugo HS
Ther Adv Med Oncol; 2019; 11():1758835919854238. PubMed ID: 31258629
[TBL] [Abstract][Full Text] [Related]
8. The CSF-1R inhibitor pexidartinib affects FLT3-dependent DC differentiation and may antagonize durvalumab effect in patients with advanced cancers.
Voissière A; Gomez-Roca C; Chabaud S; Rodriguez C; Nkodia A; Berthet J; Montane L; Bidaux AS; Treilleux I; Eberst L; Terret C; Korakis I; Garin G; Pérol D; Delord JP; Caux C; Dubois B; Ménétrier-Caux C; Bendriss-Vermare N; Cassier PA
Sci Transl Med; 2024 Jan; 16(731):eadd1834. PubMed ID: 38266104
[TBL] [Abstract][Full Text] [Related]
9. Pediatric PK/PD Phase I Trial of Pexidartinib in Relapsed and Refractory Leukemias and Solid Tumors Including Neurofibromatosis Type I-Related Plexiform Neurofibromas.
Boal LH; Glod J; Spencer M; Kasai M; Derdak J; Dombi E; Ahlman M; Beury DW; Merchant MS; Persenaire C; Liewehr DJ; Steinberg SM; Widemann BC; Kaplan RN
Clin Cancer Res; 2020 Dec; 26(23):6112-6121. PubMed ID: 32943455
[TBL] [Abstract][Full Text] [Related]
10. Prospects of Treating Tenosynovial Giant Cell Tumor through Pexidartinib: A Review.
Alsayadi YMMA; Chawla PA
Anticancer Agents Med Chem; 2021; 21(12):1510-1519. PubMed ID: 33143617
[TBL] [Abstract][Full Text] [Related]
11. CSF-1R inhibitor, pexidartinib, sensitizes esophageal adenocarcinoma to PD-1 immune checkpoint blockade in a rat model.
Omstead AN; Paskewicz M; Gorbunova A; Zheng P; Salvitti MS; Mansoor R; Reed P; Ballengee S; Wagner PL; Jobe BA; Kelly RJ; Zaidi AH
Carcinogenesis; 2022 Oct; 43(9):842-850. PubMed ID: 35552655
[TBL] [Abstract][Full Text] [Related]
12. Population Pharmacokinetic Analysis of Pexidartinib in Healthy Subjects and Patients With Tenosynovial Giant Cell Tumor or Other Solid Tumors.
Yin O; Wagner AJ; Kang J; Knebel W; Zahir H; van de Sande M; Tap WD; Gelderblom H; Healey JH; Shuster D; Stacchiotti S
J Clin Pharmacol; 2021 Apr; 61(4):480-492. PubMed ID: 33043474
[TBL] [Abstract][Full Text] [Related]
13. Pexidartinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor: safety and efficacy.
Palmerini E; Longhi A; Donati DM; Staals EL
Expert Rev Anticancer Ther; 2020 Jun; 20(6):441-445. PubMed ID: 32297819
[TBL] [Abstract][Full Text] [Related]
14. Characterizing the pharmacokinetics of panobinostat in a non-human primate model for the treatment of diffuse intrinsic pontine glioma.
Rodgers LT; Lester McCully CM; Odabas A; Cruz R; Peer CJ; Figg WD; Warren KE
Cancer Chemother Pharmacol; 2020 Apr; 85(4):827-830. PubMed ID: 31894347
[TBL] [Abstract][Full Text] [Related]
15. Plasma and cerebrospinal fluid pharmacokinetics of SU5416 after intravenous administration in nonhuman primates.
Renbarger J; Aleksic A; McGuffey L; Dauser R; Berg S; Blaney S
Cancer Chemother Pharmacol; 2004 Jan; 53(1):39-42. PubMed ID: 14551735
[TBL] [Abstract][Full Text] [Related]
16. Plasma and cerebrospinal fluid pharmacokinetics of the Akt inhibitor, perifosine, in a non-human primate model.
Cole DE; Lester-McCully CM; Widemann BC; Warren KE
Cancer Chemother Pharmacol; 2015 May; 75(5):923-8. PubMed ID: 25740692
[TBL] [Abstract][Full Text] [Related]
17. Determination of chidamide in rat plasma and cerebrospinal fluid.
Yang H; Li C; Chen Z; Mou H; Gu L
Regul Toxicol Pharmacol; 2018 Oct; 98():24-30. PubMed ID: 30008379
[TBL] [Abstract][Full Text] [Related]
18. Pexidartinib (TURALIO™): The First FDA-Indicated Systemic Treatment for Tenosynovial Giant Cell Tumor.
Monestime S; Lazaridis D
Drugs R D; 2020 Sep; 20(3):189-195. PubMed ID: 32617868
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of the Multi-kinase Inhibitor Pexidartinib: Mass Balance and Dose Proportionality.
Zahir H; Greenberg J; Hsu C; Watanabe K; Makino C; He L; LaCreta F
Clin Pharmacol Drug Dev; 2023 Feb; 12(2):159-167. PubMed ID: 36369799
[TBL] [Abstract][Full Text] [Related]
20. Colony-Stimulating Factor 1 Receptor Blockade Inhibits Tumor Growth by Altering the Polarization of Tumor-Associated Macrophages in Hepatocellular Carcinoma.
Ao JY; Zhu XD; Chai ZT; Cai H; Zhang YY; Zhang KZ; Kong LQ; Zhang N; Ye BG; Ma DN; Sun HC
Mol Cancer Ther; 2017 Aug; 16(8):1544-1554. PubMed ID: 28572167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]